Short answer
Neurocrine Biosciences Inc (NBIX) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.1B (up 41.2% year over year) with net income of $207M.
Q3 2026 key financials · XBRL
- Revenue
- $1.1B
- +41.2% YoY · +17.1% QoQ
- Net income
- $207M
- −1.4% YoY · +43.0% QoQ
- Operating margin
- 29.5%
- EPS (diluted)
- $1.96
- −4.9% YoY · +41.0% QoQ
Source: XBRL data from the Neurocrine Biosciences Inc (NBIX) Q3 2026 10-Q on SEC EDGAR. USD.
Neurocrine Biosciences Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Third-quarter revenue $1,122.7M, up $327.8M YoY from $794.9M
- Operating margin 29.5% vs 30.1% YoY, net margin 18.4% vs 26.4%
- Best product: INGREZZA sales $801.5M vs $686.6M; worst: Other sales $0 vs $5.2M
- Cash, equivalents and securities $789.7M vs $2,543.4M; operating cash flow $677.4M for nine months
- Soleno acquisition consumed $2.4B cash; $1.0B credit capacity available, funding sufficient for at least 12 months
Risk Factors
- Newly added risk: VYKAT XR safety scrutiny, August 2026 advocacy warnings followed serious adverse-event reports to FDA’s AEMS
- Most materially updated regulatory risk: FDA identified fluid retention as a potential VYKAT XR safety signal in September 2026
- Legal and compliance risk: DOJ civil investigative demand seeks INGREZZA sales and marketing documents, received August 2025
- Operational risk: four distribution customers represent over 90% of gross product sales, concentrating revenue exposure
- Financial risk: $1.0 billion secured revolver entered May 2026, with variable-rate borrowings and quarterly leverage covenants
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Neurocrine Biosciences Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.